Search

Axsome Therapeutics Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

144.58 0.77

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

139.44

Max

144.35

Pagrindiniai rodikliai

By Trading Economics

Pajamos

13M

-51M

Pardavimai

27M

218M

Pelnas, tenkantis vienai akcijai

-0.99

Pelno marža

-23.498

Darbuotojai

1,346

EBITDA

14M

-47M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+96.94% upside

Dividendai

By Acuity

Kitas uždarbis

2026-11-02

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-3.3B

7.5B

Ankstesnė atidarymo kaina

143.81

Ankstesnė uždarymo kaina

144.58

Axsome Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-10-29 20:02; UTC

News

Mizuho analyst Graig Suvannavejh lowered Axsome Therapeutics' price target to $284.00 from $316.00 while keeping an Outperform rating.

2026-10-28 20:21; UTC

Axsome Therapeutics, Inc. is trading modestly higher in after-market hours, supported by gains in the Pharmaceuticals sub-sector, shifting from a slight loss since Wednesday's close.

2026-10-27 20:01; UTC

Axsome Therapeutics, Inc. shares fell sharply, retracing from an early high and continuing a decline with five consecutive sessions of losses.

2026-10-26 21:01; UTC

Axsome Therapeutics Inc shares advanced modestly during after-market hours on Monday, marking the highest cumulative return of the session following recent pressure.

2026-10-23 23:06; UTC

Axsome Therapeutics Inc is trading modestly higher in after-market hours, in line with broader market trends despite mixed economic signals and rising oil prices.

2026-10-22 20:13; UTC

Axsome Therapeutics Inc shares are trading modestly lower in after-market hours, continuing a notably weak performance below its 20-day moving average.

2026-10-21 23:11; UTC

Axsome Therapeutics Inc is trading higher in after-market hours, rebounding from a brief dip earlier in the session and reaching its highest point of the day.

2026-10-20 23:51; UTC

Axsome Therapeutics Inc shares advanced sharply in after-market trading, rising from a low shortly after the market closed to a session high.

2026-10-19 23:56; UTC

Axsome Therapeutics Inc shares are trading higher in after-market hours, having pulled back from an initial gain shortly after the market closed.

2026-10-16 20:07; UTC

Axsome Therapeutics Inc shares are declining, consistent with broader market weakness, reaching their lowest point since Thursday's close amid a subdued trading environment.

2026-10-15 20:07; UTC

Axsome Therapeutics Inc shares are declining, following volatility earlier in the session, and remain significantly below their 20-day moving average.

2026-10-14 21:01; UTC

Axsome Therapeutics Inc shares are moving lower in after-market trading amid a broader market decline following increased inflation concerns and potential Fed interest rate hikes.

2026-10-13 20:01; UTC

Axsome Therapeutics Inc shares fell sharply, breaking a recent trend of higher daily closes, contrasting with the upward momentum observed since Monday's close.

2026-10-12 23:41; UTC

Axsome Therapeutics Inc shares advanced in after-market trading, showing gains after an initial dip, despite a broader decline over the past month.

2026-10-09 19:35; UTC

Axsome Therapeutics Inc shares fell sharply during the current market session, reflecting a broader trend of lower daily closes over the past month.

2026-10-08 23:01; UTC

Axsome Therapeutics Inc shares are modestly lower in after-market trading, continuing a downward trend since Thursday's close and remaining below its 20-day moving average.

2026-10-07 20:08; UTC

News

Axsome Therapeutics Inc shares fell as the company announced its third-quarter financial results will be released on November 2, 2026, before market open.

2026-10-06 22:35; UTC

Axsome Therapeutics Inc's shares are higher in after-market hours, despite a recent decline and nine consecutive sessions finishing lower.

2026-10-05 19:35; UTC

Axsome Therapeutics Inc shares fell, continuing a downward trend with seven consecutive sessions of lower closes since the market opened.

2026-10-02 20:12; UTC

Axsome Therapeutics Inc is trading modestly lower in after-market hours, continuing a trend with six consecutive sessions finishing lower.

2026-10-01 20:07; UTC

Axsome Therapeutics Inc shares fell sharply, closing lower than Wednesday and remaining significantly below the 20-day moving average.

2026-09-30 21:01; UTC

Axsome Therapeutics Inc's shares rose in after-market trading, supported by positive economic indicators, including stronger GDP growth and robust personal spending.

2026-09-29 20:01; UTC

News

Shares of Axsome Therapeutics fell as Deutsche Bank maintained its Buy rating but lowered the price target to $267 amid reevaluated market conditions.

2026-09-28 20:07; UTC

News

Axsome Therapeutics Inc shares fell amid a broader market downturn, despite presenting new Alzheimer’s agitation survey data at Psych Congress 2026.

2026-09-25 20:07; UTC

News

Axsome Therapeutics shares fell after Morgan Stanley cut its price target to $247 from $251, contributing to a decline near the lower end of its one-month range.

2026-09-24 20:07; UTC

Axsome Therapeutics Inc's shares advanced, recovering from four consecutive sessions of losses, though they remain below their 20-day moving average.

2026-09-23 23:35; UTC

Axsome Therapeutics Inc is trading modestly higher in after-market hours following unusual activity, though it remains significantly below its 20-day moving average.

2026-09-22 19:45; UTC

Axsome Therapeutics Inc shares fell sharply, trading below their 20-day moving average, marking three consecutive sessions of declines amid a weaker market trend.

2026-09-21 20:12; UTC

Axsome Therapeutics Inc is trading modestly lower in after-market hours, remaining near the lower end of its one-month trading range and below its 20-day moving average.

2026-09-18 19:46; UTC

Axsome Therapeutics Inc shares fell after reaching an early high, remaining below Thursday's close and stabilizing around the middle of its one-month trading range.

Akcijų palyginimas

Kainos pokytis

Axsome Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

96.94% į viršų

12 mėnesių prognozė

Vidutinis 282.625 USD  96.94%

Aukščiausias 380 USD

Žemiausias 238 USD

Remiantis 17 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Axsome Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

17 ratings

16

Pirkti

1

Laikyti

0

Parduoti

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Axsome Therapeutics Inc

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.
help-icon Live chat